Genito-urinary Cancer

News alerts, weekly reports and conference planners

BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval Korea Biomedical Review - 2 days (New A1) abiraterone / niraparib Sensitive : A1 Korea Biomedical Review - 2d	abiraterone/niraparib Sensitive: A1 - Approval Korea Biomedical Review - 2 days abiraterone / niraparib Sensitive : A1 Korea Biomedical Review - 2 days - (New A1)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval Korea Biomedical Review - 2 days (New A1) abiraterone / niraparib Sensitive : A1 Korea Biomedical Review - 2d	abiraterone/niraparib Sensitive: A1 - Approval Korea Biomedical Review - 2 days abiraterone / niraparib Sensitive : A1 Korea Biomedical Review - 2 days - (New A1)
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A1 - Approval Merck (MSD) Press Release - 6 days (New B) pembrolizumab + enfortumab vedotin-ejfv Sensitive : A1 Merck (MSD) Press Release - 6d	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A1 - Approval Merck (MSD) Press Release - 6 days pembrolizumab + enfortumab vedotin-ejfv Sensitive : A1 Merck (MSD) Press Release - 6 days - (New B)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	belzutifan Sensitive: A2 - Guideline Merck (MSD) Press Release - 1 week (New B) belzutifan Sensitive : A2 Merck (MSD) Press Release - 1wk	belzutifan Sensitive: A2 - Guideline Merck (MSD) Press Release - 1 week belzutifan Sensitive : A2 Merck (MSD) Press Release - 1 week - (New B)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials Eur Urol Oncol - 1 week (New C3) PARP inhibitor Sensitive : C3 Eur Urol Oncol - 1wk	PARP inhibitor Sensitive: C3 – Early Trials Eur Urol Oncol - 1 week PARP inhibitor Sensitive : C3 Eur Urol Oncol - 1 week - (New C3)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials Eur Urol Oncol - 1 week (New C3) PARP inhibitor Sensitive : C3 Eur Urol Oncol - 1wk	PARP inhibitor Sensitive: C3 – Early Trials Eur Urol Oncol - 1 week PARP inhibitor Sensitive : C3 Eur Urol Oncol - 1 week - (New C3)
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	avelumab Sensitive: A1 - Approval Eur Urol - 2 weeks (New B) avelumab Sensitive : A1 Eur Urol - 2wk	avelumab Sensitive: A1 - Approval Eur Urol - 2 weeks avelumab Sensitive : A1 Eur Urol - 2 weeks - (New B)
SETD2 deletion	Clear Cell Renal Cell Carcinoma	SETD2 deletion	Clear Cell Renal Cell Carcinoma	talazoparib Sensitive: D – Preclinical Cancer Res - 2 weeks (New D) talazoparib Sensitive : D Cancer Res - 2wk	talazoparib Sensitive: D – Preclinical Cancer Res - 2 weeks talazoparib Sensitive : D Cancer Res - 2 weeks - (New D)
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: A1 - Approval Ann Oncol - 3 weeks (New B) enfortumab vedotin-ejfv Sensitive : A1 Ann Oncol - 3wk	enfortumab vedotin-ejfv Sensitive: A1 - Approval Ann Oncol - 3 weeks enfortumab vedotin-ejfv Sensitive : A1 Ann Oncol - 3 weeks - (New B)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	niraparib Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) niraparib Sensitive : A2 NCCN - 3wk	niraparib Sensitive: A2 - Guideline NCCN - 3 weeks niraparib Sensitive : A2 NCCN - 3 weeks - (New A2)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	niraparib Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) niraparib Sensitive : A2 NCCN - 3wk	niraparib Sensitive: A2 - Guideline NCCN - 3 weeks niraparib Sensitive : A2 NCCN - 3 weeks - (New A2)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	ABT-869 Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) ABT-869 Sensitive : C3 BMC Cancer - 3wk	ABT-869 Sensitive: C3 – Early Trials BMC Cancer - 3 weeks ABT-869 Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	midostaurin Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) midostaurin Sensitive : C3 BMC Cancer - 3wk	midostaurin Sensitive: C3 – Early Trials BMC Cancer - 3 weeks midostaurin Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	vinblastine Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) vinblastine Sensitive : C3 BMC Cancer - 3wk	vinblastine Sensitive: C3 – Early Trials BMC Cancer - 3 weeks vinblastine Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	vorinostat Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) vorinostat Sensitive : C3 BMC Cancer - 3wk	vorinostat Sensitive: C3 – Early Trials BMC Cancer - 3 weeks vorinostat Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
TNFRSF18-H	Renal Cell Carcinoma	TNFRSF18-H	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials Eur Rev Med Pharmacol Sci - 3 weeks (New C3) nivolumab Sensitive : C3 Eur Rev Med Pharmacol Sci - 3wk	nivolumab Sensitive: C3 – Early Trials Eur Rev Med Pharmacol Sci - 3 weeks nivolumab Sensitive : C3 Eur Rev Med Pharmacol Sci - 3 weeks - (New C3)
Low NLR	Renal Cell Carcinoma	Low NLR	Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sunitinib Sensitive : C3 Cancer Control - 3wk	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sunitinib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
Low NLR	Renal Cell Carcinoma	Low NLR	Renal Cell Carcinoma	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sorafenib Sensitive : C3 Cancer Control - 3wk	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sorafenib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
Low MLR	Renal Cell Carcinoma	Low MLR	Renal Cell Carcinoma	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sorafenib Sensitive : C3 Cancer Control - 3wk	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sorafenib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
Low MLR	Renal Cell Carcinoma	Low MLR	Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sunitinib Sensitive : C3 Cancer Control - 3wk	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sunitinib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : C1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : C1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide capsule Sensitive: A1 - Approval enzalutamide capsule Sensitive : A1	enzalutamide capsule Sensitive: A1 - Approval enzalutamide capsule Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	etoposide IV Sensitive: A1 - Approval etoposide IV Sensitive : A1	etoposide IV Sensitive: A1 - Approval etoposide IV Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	ifosfamide Sensitive: A1 - Approval ifosfamide Sensitive : A1	ifosfamide Sensitive: A1 - Approval ifosfamide Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1

Genito-urinary Cancer

Associations(1362)

Associations
(1362)